Daily weight-loss tablets are widening the market for GLP-1 treatments and boosting pharmaceutical expectations.
Analysts say easier-to-take pills could make the drugs more mainstream and help create a $200bn industry.
Novo Nordisk has launched the first oral Wegovy in the US, with rapid early uptake.
Many patients are switching from injections because tablets are cheaper, simpler and need no refrigeration.
Some also report steadier appetite control across the week.
Rival Eli Lilly is preparing its own pill, intensifying the race.
Oral drugs are slightly less effective than injections, so people with severe obesity may still choose jabs.
Pills are expected to attract new users who are overweight or mildly obese.
High prices, side-effects and limited public coverage remain barriers.
However, falling costs, new insurance support and rising global obesity are driving demand.
Drugmakers and researchers say most eligible patients still receive no treatment.
